Purchase this article with an account.
Mark Taegon Baik, JongYoon Choi, Kyungwook Min, Laurence Feraille, Elisabeth Raymond, Elena Pierre-Paul; Dry Eye: Efficacy evaluation of three synthetic peptides from Chondrocyte-Derived ExtraCellular Matrix (CDEM) in comparison to lifitegrast, cyclosporine A, diquafosol sodium and sodium hyaluronate in a mouse model. Invest. Ophthalmol. Vis. Sci. 2019;60(9):291.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Dry eye disease is a complex, multifactorial pathology characterized by corneal epithelium lesions and inflammation. In this study, we investigated the effect of three synthetic peptides, YDE-010, YDE-011, YDE-043 from chondrocyte-derived extracellular matrix (CDECM) in a murine model of dry eye induced by scopolamine administration and controlled environmental room.
Six to nine-week-old female C57BL6 mice with tail patches of scopolamine (replaced every other day) were housed in controlled environment room (humidity <25%) to induce dry eye for 10 days. After stress induced by dessication, groups of 10 mice each received for 10 days one of three peptides (1%), or vehicle or lifitegrast (Xiidra®), cyclosporine A (Restasis®), diquafosol sodium (Diquas®) and sodium hyaluronate (Vismed®) through topical administration of 5µL four to five times per day in both eyes. To rule out a vehicle effect an additional group received no treatment. The tear volume and the corneal staining score were measured at baseline, after the desiccation stress (Day 10) and 3, 5, 7 and 10 days after treatment.
As expected, signs of experimental dry eye were observed for all animals after a desiccating stress of 10 days. After desiccating stress period, tear production improved over the time in all groups. Compared to the untreated and vehicle control groups, the mice treated with topical application of the YDE-010, YDE-011 and YDE-043 formulations showed significant improvements in corneal staining. Versus to the vehicle control group, the more relevant improvement was observed with the YDE-011 peptide with a reduction of CFS by 30% and 47% after 3 and 5 days of treatment. No significant improvement in corneal staining was observed for the mice treated with cyclosporine A (Restasis®), diquafosol (Diquas®), sodium hyaluronate (Vismed®) and lifitegrast (Xiidra®).
In this murine experimental model of dry eye, the three synthetic peptides YDE-010, YDE-011, YDE-043 from chondrocyte-derived extracellular matrix (CDECM) improved corneal integrity and were more effective than prescription treatments.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only